Genomics Is Coming To Malaysia, But Will It Reach Everyone?

Malaysia is rapidly integrating genomic technologies and precision health platforms into its national healthcare landscape through initiatives like MyGenom and various private-sector partnerships. While these advancements offer transformative potential for treating rare diseases, cancer, and chronic conditions, experts warn that high costs and systemic barriers could limit access to the wealthy. To ensure equitable distribution, the sector must address ethical, legal, and social implications while establishing robust public funding and governance frameworks.

Malaysia is transitioning into a new era of precision medicine, driven by national initiatives such as MyGenom alongside academic collaborations, private laboratories, and international industry partnerships. Associate Professor Dr. Teguh Haryo Sasongko of IMU University highlights that genomic technologies, molecular diagnostics, and targeted therapies are already entering the health system to address rare diseases, cancer, and pharmacogenomics. These tools promise earlier diagnoses, better risk prediction, and more precise treatment selections, positioning Malaysia as an emerging healthcare market for global genomics companies looking for data and clinical adoption.

Despite this technological progress, significant barriers threaten to turn precision medicine into a premium product accessible only to affluent patients. Beyond the high cost of sequencing, the entire precision medicine pathway—including specialist consultations, genetic counseling, and follow-up monitoring—remains prohibitively expensive for many families. Sasongko notes that patients with higher education, digital literacy, and proximity to urban specialist centers are far more likely to successfully navigate the complex referral and interpretation process, potentially leaving rural and lower-income populations behind long before a genomic result is even produced.

To prevent a justice gap, the sector must prioritize Ethical, Legal, and Social Implications (ELSI) as a foundational governance requirement rather than an academic afterthought. Concerns regarding data privacy, insurance discrimination, and the clinical utility of results require a national roadmap and transparent public funding to ensure the ecosystem favors public interest over private consumption. Sasongko argues that public investment should focus on high-value areas like actionable rare diseases and cancer molecular testing, ensuring that the necessary infrastructure—such as counseling, workforce development, and data protection—is funded alongside the tests themselves to create a truly inclusive healthcare future.